[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"NovoBliss Research Pvt Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":89},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100617910","clinical-study-to-assess-safety-effectiveness-and-in-use-tolerability-of-saffron-extract-capsules-for-improving-skin-health-and-reducing-signs-of-aging-on-healthy-adult-male-and-female-subjects-100617910",false,"NCT07324759","Clinical Study to Assess Safety, Effectiveness and In-Use Tolerability of Saffron Extract Capsules for Improving Skin Health and Reducing Signs of Aging on Healthy Adult Male and Female Subjects.","Effect of Saffron Extract Capsule Supplement on Skin Rejuvenation and Anti-Ageing in Healthy Adult Male and Female Subjects: Randomised, Double-Blind, Two-Group, Prospective, Multi-Centre Exploratory Study","GLOW","Inclusion Criteria:\n\n1. Age: 30 to 55 years (both inclusive) at the time of consent.\n2. Sex: Adult male and female having wrinkles and fine lines at crow feet's area, facial hyperpigmentation and dark spots such as tan, pimple marks, sunspots, age spots, uneven skin tone on both side of face.\n3. Females of childbearing potential should have a self-reported negative urine pregnancy test at the time of screening visit.\n4. Subjects should not have used any cosmetic, nutraceutical or therapeutic products for skin ageing in last 1 month.\n5. Subjects must be willing to stop using any cosmetics or any medical products for skin ageing for the duration of the study.\n6. Subjects are not allowed to participate in any other study until this study is complete.\n7. Subjects must be willing and able to follow the study directions and to return for all specified visits with the product.\n8. Subjects must agree to record each use of the test products in the subject's diary card on daily basis.\n9. Subjects must agree to record medication use during the study.\n\nExclusion Criteria:\n\n1. Subjects who are on steroids for last six months and using immunosuppressive, anti-inflammatory, or hormone-modulating medications that may interfere with study outcomes.\n2. Subjects who have used any cosmetic, nutraceutical or therapeutic products for skin last one months.\n3. Subjects currently using any oral supplement and topical products containing kojic acid, glycolic acid, niacinamide, alpha arbutin, vitamin C, retinoids, peptides, exfoliating acids, or any other skin-lightening, anti-ageing, or depigmenting agents within the past 4 weeks.\n4. Subjects with a known history of hypersensitivity, allergic reactions, or intolerance (such as drowsiness, stomach discomfort, nausea, or vomiting).\n5. Subjects with other dermatologic diseases whose presence or products could interfere with the assessment of study.\n6. Subjects that are pregnant and\u002For breastfeeding.\n7. The subject has a known allergy or sensitivity to product ingredients.\n8. Subjects if do not agree to limit sun exposure to affected areas such as face during prolonged sun exposure.\n9. The subject has any other skin conditions i.e. cuts, scratches, ring worms, etc. which in the opinion of the Investigator, will interfere with the study results or will create undue risk for the subject.\n10. The subject has any of the conditions or factors that the Investigator believes may affect the response of the skin or the interpretation of the test results.\n11. The subject is currently taking or has taken any medication, which the Investigator believes may influence the interpretation of the data.\n12. Any other condition which could warrant exclusion from the study, as per the dermatologist's\u002Finvestigator's discretion.",true,"ALL","30 Years","55 Years",{"count":22,"type":23},50,"ESTIMATED","INTERVENTIONAL",[26],"NA","This is a randomized, double-blind, comparative, two-arm, prospective, interventional, multi-centre clinical study to evaluate the safety, efficacy, and in-use tolerability of test products, standardized saffron extract capsules, on skin rejuvenation and age-defying benefits in healthy adult male and female subjects.",[29,30,31,32],"Wrinkles","Fine Lines","Hyperpigmentation","Dark Spots","NOT_YET_RECRUITING","2025-12-24",{"date":36,"type":37},"2026-01-07","ACTUAL",{"date":39,"type":23},"2026-01-01",{"date":41,"type":23},"2026-05-30",{"name":43,"class":44},"NovoBliss Research Pvt Ltd","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":17,"sex":18,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":24,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100607999","dermatological-safety-and-skin-compatibility-evaluation-of-test-products-100607999","NCT07195851","Dermatological Safety and Skin Compatibility Evaluation of Test Products","Dermatological Safety and Skin Compatibility Evaluation of Test Product Following Cosmetics Europe: Product Test Guidelines for Assessment of Human Skin Compatibility (Colipa Standard, 1997)","Inclusion Criteria:\n\n1. Age: 18-65 years (both inclusive) at the time of consent.\n2. Sex: Males and non-pregnant\u002Fnon-lactating females (preferably equal number of males and females).\n3. Subject with normal Fitzpatrick skin type III to VI (Human skin colour determination scale).\n4. Females of childbearing potential must have a self-reported negative pregnancy test.\n5. Subject who do not have any previous history of adverse skin conditions and are not under any medication likely to interfere with the results.\n6. Subject is in good general health as determined by the Investigator on the basis of medical history.\n7. Subjects is willing to maintain the test patches in designated positions for 24 Hours.\n8. Subject is willing and able to follow the study directions, to participate in the study, returning for all specified visits.\n9. Subject must be able to understand and provide written informed consent to participate in the study.\n10. Subject is willing to refrain from vigorous physical exercise during the study period and follow all the instruction given.\n11. For Sensitive Specific Skin Study Only:\n\n    * Subject scoring greater than 30 for Section 2 - Sensitive v\u002Fs Resistant skin in modified Dr Baumann's skin type questionnaire.\n    * Subject with sensitive skin as confirmed by Lactic Acid stinging test.\n\nExclusion Criteria:\n\n1. Subject having skin irritation, blemishes, excessive hair, moles, pigmentation, pimples, marks (e.g. tattoos (within the previous 3 months), scars, sunburn), open wounds, cuts, abrasions, irritation symptoms or any dermatological condition on the test site(s) i.e. back that can interfere with the reading.\n2. Medication which may affect skin response and\u002For past medical history.\n3. Subject having history of diabetes\n4. Subject have history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months.\n5. Subject suffering from any active clinically significant skin diseases which may contraindicate.\n6. Subject having history of any skin diseases including eczema, atopic dermatitis or active cancer.\n7. Participation in any patch test for irritation or sensitization within the last four weeks.\n8. Subject having history of asthma or COPD (Chronic obstructive pulmonary disease).\n9. Use of any:\n\n   i. Prescribed or over-the-counter (OTC) anti-inflammatory drug within five (5) days prior to application. ii. Antihistamine medication or immunosuppressive drugs within seven (7) days prior to first patch application. iii. Systemic or topical corticosteroids at patch site within four (4) weeks of test product application (steroidal nose drops and\u002For eye drops are permitted)\n10. Topical drugs used at application site.\n11. Subject with Self-reported Immunological disorders such as HIV positive, AIDS and\u002For systemic lupus erythematous.\n12. Individual who has a medical condition or is taking or has taken a medication which, in the Investigator's judgment, makes the subject ineligible or places the subject at undue risk.\n13. Subject with known allergy or sensitization to medical adhesives, bandages.\n14. Participation in other patch study simultaneously.","18 Years","65 Years",{"count":55,"type":23},26,[26],"Dermatological Safety and Skin Compatibility Evaluation of Test Product following Cosmetics Europe: Product Test Guidelines for Assessment of Human Skin Compatibility (Colipa Standard, 1997)",[59],"Healthy Subjects","2025-09-24",{"date":62,"type":37},"2025-09-29",{"date":64,"type":23},"2025-09",{"date":66,"type":23},"2025-10",{"name":43,"class":44},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":18,"minAge":52,"maxAge":53,"enrollmentInfo":75,"targetDuration":4,"studyType":24,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":4},"100600525","clinical-study-to-assess-the-safety-and-efficacy-of-acv-moringa-effervescent-tablet-intake-on-weight-management-in-overweight-and-class-i-obese-study-participants-100600525","NCT07098624","Clinical Study to Assess the Safety and Efficacy of ACV Moringa Effervescent Tablet Intake on Weight Management in Overweight and Class I Obese Study Participants","A Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Single-Centre, Clinical Study to Evaluate the Safety and Efficacy of Intake of ACV Moringa on the Degree of Weight Change in Overweight and Class I Obese Study Participants.","Inclusion Criteria:\n\n1. Age: 18- 65 years (both inclusive) at the time of consent.\n2. Sex: Males and non-pregnant\u002Fnon-lactating females (preferably equal number of males and females).\n3. Females of childbearing potential must have a self-reported negative urine pregnancy.\n4. Female of childbearing potential must have a reported negative pregnancy during screening and the end of the study\n5. Subject is in good general health as determined by the Investigator on the basis of medical history.\n6. Subjects who are classified as overweight (BMI 25.0-29.9 kg\u002Fm²) or as having Class I obesity (BMI 30.0-34.9 kg\u002Fm²).\n7. Subjects with a total body fat percentage exceeding 25% for men and 30% for women using Bioimpedance test.\n8. Subject is willing to forgo liposuction procedures or any weight loss therapy 3 months prior to and for the duration of the study.\n9. Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study.\n10. If the female subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device\u002Finjection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation.\n11. If currently using hormonal contraception, has been using this form of contraception for at least 6 months and agrees to continue using the same contraception for the duration of the study.\n12. Subject who agree to consume a vegetarian\u002Fnon-vegetarian diet of approximately 2000 kcal\u002Fday (14% protein, 25%Fat and 61% carbohydrate).\n13. Subjects willing to follow the given diet and maintain their physical activity by a Diet and physical activity diary.\n14. Subjects must possess an Android smartphone to facilitate daily app login and study-related activities.\n15. Subjects are willing to give written informed consent and are willing to follow the study procedure.\n16. Subjects who commit not to use any other medication for weight management other than the test treatment for the entire duration of the study.\n17. Willing to use test treatment throughout the study period.\n18. Subject is willing and able to follow the study directions, to participate in the study, returning for all specified visits.\n\nExclusion Criteria:\n\n1. Subjects BMI is between less than 25 and greater than 35 kg\u002Fm2.\n2. Subjects having past or present history or clinically significant findings indicating cardiovascular disease, type 2 diabetes mellitus, hypertension, endocrine, pulmonary, neurological or psychological disorders, hypo or hyperthyroidism and renal disorders.\n3. Subjects with a history of gastrointestinal disorders, including chronic gastritis, gastric discomfort, or any diagnosed gastrointestinal conditions.\n4. Subjects having drug and alcohol abuse.\n5. Smokers and tobacco users.\n6. Subjects having more than 5 kg variation in body weight within 3 months before study entry.\n7. Subjects using other weight loss medications, as well as stimulants, laxatives or diuretics taken solely for the purpose of weight loss.\n8. Undergone surgery before 30 days of screening or planning to undergo surgery within the study period.\n9. Subjects having chronic diarrhoeal disorders, cancer, hepatic dysfunction, and human immunodeficiency virus (HIV) infection.\n10. Participation in other drugs, investigational medicinal product, any herbal products and\u002For cosmetics intended to weight loss clinical trials within 3 months before enrolment in this trial.\n11. Any other diseases\u002Fco-morbidity that is considered by the Investigator as an exclusion.\n12. With severe hepatic and\u002For renal impairment, liver enzyme level (ALT and\u002For AST) is greater than 2.5 times the upper normal limit.\n13. Taking antibiotic therapy, anti-depressant treatment or treatment related to anxiety in the month preceding the study,\n14. Taking anti-depressant treatment or treatment related to anxiety Subject in a state of depression.\n15. Non-stable weight during the last 6 months (\\>5% change in total weight)\n16. Consuming food supplements or functional foods known to have an influence on weight management in the month preceding the inclusion and\u002For likely to take during the test\n17. Following or having followed a hypocaloric diet (energy intake \\\u003C1,500 kCal\u002Fday) in the month preceding inclusion and\u002For likely to undertake this diet during the test.\n18. Diagnosed eating disorders (bulimia, anorexia nervosa, vomiting),\n19. Using topical anti-cellulite treatments.\n20. Pregnant or breastfeeding or planning to become pregnant during the study period.\n21. Subject has a history of chronic illness which may influence the cutaneous state.\n22. Subjects participating in other similar nutraceuticals, food, supplemental or therapeutic trials within the last four weeks.\n23. Any other condition which could warrant exclusion from the study, as per the Investigator's discretion.",{"count":76,"type":23},66,[26],"A Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Single-Centre, Clinical Study to Evaluate the Safety and Efficacy of Intake of ACV Moringa on the Degree of Weight Change in Overweight and Class I Obese Study Participants",[80],"Obese or Overweight Healthy Volunteers","2025-07-31",{"date":83,"type":37},"2025-08-01",{"date":85,"type":23},"2025-07-24",{"date":87,"type":23},"2025-11-04",{"name":43,"class":44},""]